Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H2CasMab-2
- Development stage
- Preclinical
- Lead developer
- Tohoku University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
H2CasMab-2 is a cancer-specific monoclonal antibody (CasMab) targeting the human epidermal growth factor receptor 2 (HER2). Developed by researchers at Tohoku University, it is designed to bind specifically to a locally misfolded region of HER2 that is present on cancer cells but absent or inaccessible on normal tissues. This cancer-specific binding profile aims to reduce off-target adverse effects compared to conventional anti-HER2 therapies. Preclinical evaluations of various versions, including the humanized IgG1 form (humH2CasMab-2), have demonstrated significant antitumor efficacy in breast cancer xenograft models. While it exhibits lower antibody-dependent cellular cytotoxicity (ADCC) than trastuzumab, it shows significantly higher complement-dependent cytotoxicity (CDC), suggesting a distinct immunological mechanism for its therapeutic effect.
- Other names
- humanized cancer-specific anti-HER2 monoclonal antibody
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on H2CasMab-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H2CasMab-2.